High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

Harrison, C N

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. [electronic resource] - British journal of cancer Oct 1999 - 476-83 p. digital

Publication Type: Journal Article

0007-0920

10.1038/sj.bjc.6690718 doi


Acute Disease
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Carmustine--administration & dosage
Child
Child, Preschool
Chlorambucil--administration & dosage
Cohort Studies
Combined Modality Therapy
Cytarabine--administration & dosage
Doxorubicin--administration & dosage
Etoposide--administration & dosage
Female
Hematopoietic Stem Cell Transplantation
Hodgkin Disease--drug therapy
Humans
Incidence
Infant
Leukemia, Myeloid--chemically induced
Life Tables
Lomustine--administration & dosage
Male
Mechlorethamine--administration & dosage
Melphalan--administration & dosage
Middle Aged
Myelodysplastic Syndromes--chemically induced
Neoplasms, Second Primary--chemically induced
Podophyllotoxin--administration & dosage
Prednisolone--administration & dosage
Prednisone--administration & dosage
Procarbazine--administration & dosage
Retrospective Studies
Risk
Salvage Therapy--adverse effects
Vinblastine--administration & dosage
Vincristine--administration & dosage